Gene therapy: Vector technology and clinical applications

Sunyong Tang, Kenneth Cornetta

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The ability to introduce genetic material into target cells has tremendous potential as a novel means for disease treatment and correction. While gene therapy is still in clinical trials, the past 20 years has seen the development of a large armamentarium of plasmid and viral vectors for human use. Initial trials focused on the correction of genetic diseases, but vectors are now available to deliver pharmacologic agents, reengineer cells, or express ribozyme and inhibitory RNAs that downregulate gene expression. Currently the majority of clinical trials have been in cancer. Approaches directed at malignancies include reengineering of autologous T cells to recognize tumor antigens and eliminate cancer cells, introduction of DNA repair genes into hematopoietic cells to protect them from chemotherapy and foster dose escalation, and introduction of immune stimulatory molecules to foster cancer cell recognition by the immune system. This chapter provides an introduction to gene therapy by illustrating the technology and discussing current clinical applications.

Original languageEnglish
Title of host publicationMolecular Genetic Pathology: Second Edition
PublisherSpringer New York
Pages399-412
Number of pages14
ISBN (Print)9781461448006, 1461447992, 9781461447993
DOIs
StatePublished - Mar 1 2014

Fingerprint

Genetic Therapy
Technology
Neoplasms
Clinical Trials
Disease Vectors
Genetic Vectors
Catalytic RNA
Inborn Genetic Diseases
Neoplasm Antigens
DNA Repair
Genes
Immune System
Plasmids
Down-Regulation
RNA
T-Lymphocytes
Gene Expression
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tang, S., & Cornetta, K. (2014). Gene therapy: Vector technology and clinical applications. In Molecular Genetic Pathology: Second Edition (pp. 399-412). Springer New York. https://doi.org/10.1007/978-1-4614-4800-6-13

Gene therapy : Vector technology and clinical applications. / Tang, Sunyong; Cornetta, Kenneth.

Molecular Genetic Pathology: Second Edition. Springer New York, 2014. p. 399-412.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tang, S & Cornetta, K 2014, Gene therapy: Vector technology and clinical applications. in Molecular Genetic Pathology: Second Edition. Springer New York, pp. 399-412. https://doi.org/10.1007/978-1-4614-4800-6-13
Tang S, Cornetta K. Gene therapy: Vector technology and clinical applications. In Molecular Genetic Pathology: Second Edition. Springer New York. 2014. p. 399-412 https://doi.org/10.1007/978-1-4614-4800-6-13
Tang, Sunyong ; Cornetta, Kenneth. / Gene therapy : Vector technology and clinical applications. Molecular Genetic Pathology: Second Edition. Springer New York, 2014. pp. 399-412
@inbook{78a527361a3441188fcb7cf88b985d40,
title = "Gene therapy: Vector technology and clinical applications",
abstract = "The ability to introduce genetic material into target cells has tremendous potential as a novel means for disease treatment and correction. While gene therapy is still in clinical trials, the past 20 years has seen the development of a large armamentarium of plasmid and viral vectors for human use. Initial trials focused on the correction of genetic diseases, but vectors are now available to deliver pharmacologic agents, reengineer cells, or express ribozyme and inhibitory RNAs that downregulate gene expression. Currently the majority of clinical trials have been in cancer. Approaches directed at malignancies include reengineering of autologous T cells to recognize tumor antigens and eliminate cancer cells, introduction of DNA repair genes into hematopoietic cells to protect them from chemotherapy and foster dose escalation, and introduction of immune stimulatory molecules to foster cancer cell recognition by the immune system. This chapter provides an introduction to gene therapy by illustrating the technology and discussing current clinical applications.",
author = "Sunyong Tang and Kenneth Cornetta",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/978-1-4614-4800-6-13",
language = "English",
isbn = "9781461448006",
pages = "399--412",
booktitle = "Molecular Genetic Pathology: Second Edition",
publisher = "Springer New York",

}

TY - CHAP

T1 - Gene therapy

T2 - Vector technology and clinical applications

AU - Tang, Sunyong

AU - Cornetta, Kenneth

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The ability to introduce genetic material into target cells has tremendous potential as a novel means for disease treatment and correction. While gene therapy is still in clinical trials, the past 20 years has seen the development of a large armamentarium of plasmid and viral vectors for human use. Initial trials focused on the correction of genetic diseases, but vectors are now available to deliver pharmacologic agents, reengineer cells, or express ribozyme and inhibitory RNAs that downregulate gene expression. Currently the majority of clinical trials have been in cancer. Approaches directed at malignancies include reengineering of autologous T cells to recognize tumor antigens and eliminate cancer cells, introduction of DNA repair genes into hematopoietic cells to protect them from chemotherapy and foster dose escalation, and introduction of immune stimulatory molecules to foster cancer cell recognition by the immune system. This chapter provides an introduction to gene therapy by illustrating the technology and discussing current clinical applications.

AB - The ability to introduce genetic material into target cells has tremendous potential as a novel means for disease treatment and correction. While gene therapy is still in clinical trials, the past 20 years has seen the development of a large armamentarium of plasmid and viral vectors for human use. Initial trials focused on the correction of genetic diseases, but vectors are now available to deliver pharmacologic agents, reengineer cells, or express ribozyme and inhibitory RNAs that downregulate gene expression. Currently the majority of clinical trials have been in cancer. Approaches directed at malignancies include reengineering of autologous T cells to recognize tumor antigens and eliminate cancer cells, introduction of DNA repair genes into hematopoietic cells to protect them from chemotherapy and foster dose escalation, and introduction of immune stimulatory molecules to foster cancer cell recognition by the immune system. This chapter provides an introduction to gene therapy by illustrating the technology and discussing current clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=84929875819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929875819&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4800-6-13

DO - 10.1007/978-1-4614-4800-6-13

M3 - Chapter

AN - SCOPUS:84929875819

SN - 9781461448006

SN - 1461447992

SN - 9781461447993

SP - 399

EP - 412

BT - Molecular Genetic Pathology: Second Edition

PB - Springer New York

ER -